Big Changes in AML Care as Targeted Therapy Options Expand

About this episode

Dr. Amir Fathi discusses the expanding treatment options for acute myeloid leukemia with Dr. Robert A. Figlin.

Options for the treatment of acute myeloid leukemia (AML) are rapidly expanding, says Amir Fathi, MD, associate professor of medicine at Harvard Medical School in Boston and program director of the Center for Leukemia at Massachusetts General Hospital. “Over the course of the last 10 to 12 years, there have been a series of approvals, predominantly for targeted therapies,” he explains. Speaking with Robert A. Figlin, MD, the interim director of Cedars-Sinai Cancer in Los Angeles and Steven Spielberg Family Chair in Hematology-Oncology, Dr. Fathi outlines how and when to look for mutations in AML and key considerations for various targeted therapies. He also shares what developments he is anticipating. “I’m most excited about where we’re moving in the upfront setting.” Dr. Fathi reported various financial relationships. Dr. Figlin reported various financial relationships.

People in this episode

Host: Robert A. Figlin, MD

Guest: Amir Fathi, MD

Topics covered

• acute myeloid leukemia
• targeted therapies
• mutations in AML
• treatment options
• oncology advancements

Keywords

• AML
• targeted therapy
• mutations
• oncology
• treatment advancements

Mentioned in this episode

Organizations: Harvard Medical School, Massachusetts General Hospital, Cedars-Sinai Cancer

More episodes of Oncology News Central Peer-Spectives

• “Not a Straightforward Decision”: What to Do While Waiting on a Practice Change in Breast Cancer Care · April 29, 2026 · 11 min
• New Targeted Therapies Make Breast Cancer Treatment Decisions “a Bit of a Moving Target” · April 21, 2026 · 9 min
• Advances in ESR1-Mutated Breast Cancer Care Lead to “Complex Situation” in Clinic · April 17, 2026 · 12 min
• Tackling “the Biggest Question That Everyone Is Asking” in Breast Cancer Care · April 2, 2026 · 14 min
• Shared Decision Making and Toxicity Management in EGFR- Mutated Advanced NSCLC · December 18, 2025 · 12 min
• “Where the Real Answer Lies”: How CNS Disease Influences EGFR-Mutated NSCLC Treatment Decisions · December 18, 2025 · 15 min